• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: 30% of T2D patients don’t start insulin therapy when recommended

September 14, 2017 By Sarah Faulkner

Insulin
Credit: Bruce Blausen

Research from Brigham & Women’s Hospital, supported by Sanofi (NYSE:SNY), found that 30% of people with Type II diabetes don’t begin insulin therapy when it’s first recommended to them.

On average, these patients are delaying treatment by two years, the researchers reported. The team’s work was published in the journal of Diabetic Medicine.

“Unfortunately this isn’t uncommon, patients being reluctant to start insulin therapy when it’s recommended,” principal investigator Dr. Alexander Turchin said in prepared remarks. “Many clinicians have encountered this phenomenon, but until our study it was not known just how prevalent delays in insulin initiation are. As physicians, we need to make sure that these patients are making fully informed decisions and that we understand their perspective to ensure they are treated effectively.”

The researchers used a computer program to analyze electronic physician notes of patients at Brigham & Women’s Hospital from 2000 to 2014, identifying patients with Type II diabetes who initially declined insulin therapy.

The analysis included 3,295 patients and found that nearly one-third of them declined to initiate insulin therapy when it was recommended to them by a doctor. People who declined at first and later accepted the recommendation, on average, began treatment more than two years later, the team reported.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development Tagged With: Brigham & Women's Hospital, Sanofi-Aventis

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS